

Irene Cacciola

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1303178/irene-cacciola-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

2,854
citations

20
h-index

53
g-index

82
ext. papers

3,311
ext. citations

4.7
avg, IF

4.32
L-index

#	Paper	IF	Citations
53	Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. <i>New England Journal of Medicine</i> , 1999 , 341, 22-6	59.2	579
52	Occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2007 , 46, 160-70	13.4	383
51	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. <i>Gastroenterology</i> , 2004 , 126, 102-10	13.3	327
50	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018 , 155, 411-421.e4	13.3	201
49	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018 , 391, 2417-2429	4.0	176
48	Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. <i>Journal of Hepatology</i> , 2014 , 61, 408-17	13.4	165
47	Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. <i>Cancer</i> , 2006 , 106, 1326-30	6.4	105
46	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 688-695	6.1	104
45	Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. <i>Hepatology</i> , 1997 , 26, 495-9	11.2	99
44	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019 , 71, 265-273	13.4	80
43	Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 696-700	13.4	71
42	Replicative and transcriptional activities of hepatitis B virus in patients coinfecting with hepatitis B and hepatitis delta viruses. <i>Journal of Virology</i> , 2011 , 85, 432-9	6.6	68
41	Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. <i>Hepatology</i> , 2000 , 31, 507-12	11.2	64
40	Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. <i>Journal of Hepatology</i> , 1999 , 30, 1023-7	13.4	50
39	Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. <i>Journal of Hepatology</i> , 2002 , 36, 426-32	13.4	45
38	Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1518-23	0.7	38
37	The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. <i>Liver International</i> , 2017 , 37, 71-79	7.9	37

36	Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. <i>Journal of Hepatology</i> , 2004 , 40, 515-9	13.4	35
35	TT virus has a ubiquitous diffusion in human body tissues: analyses of paired serum and tissue samples. <i>Journal of Viral Hepatitis</i> , 2003 , 10, 95-102	3.4	24
34	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1275-1282	0.7	23
33	Atrial fibrillation in patients with cirrhosis. <i>Liver International</i> , 2016 , 36, 395-400	7.9	16
32	Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care. <i>Internal and Emergency Medicine</i> , 2017 , 12, 181-186	3.7	14
31	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
30	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021 , 74, 340-349	13.4	11
29	Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. <i>Digestive and Liver Disease</i> , 2011 , 43, 996-1000	3.3	10
28	Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the ANSWER study. <i>Journal of Hepatology</i> , 2017 , 66, S93	13.4	9
27	Elective endoscopic variceal ligation is not a risk factor for bacterial infection in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2018 , 50, 366-369	3.3	9
26	Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 333-337	3.4	8
25	Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. <i>Liver International</i> , 2018 , 38, 1220-1229	7.9	8
24	Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naive patients with HCV genotype-1b infection. <i>Antiviral Therapy</i> , 2015 , 20, 245-7	1.6	7
23	Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study. <i>Liver International</i> , 2005 , 25, 555-63	7.9	7
22	Erectile dysfunction in compensated liver cirrhosis. <i>Digestive and Liver Disease</i> , 2019 , 51, 843-849	3.3	7
21	Fever and rhomboid target lesion in decompensated cirrhosis. <i>Lancet Infectious Diseases</i> , 2012 , 12, 576	25.5	6
20	Fibroscan: a new noninvasive method for evaluation of liver dysfunction in Turner syndrome. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 183-8	4.6	6
19	Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography. <i>Medicine (United States)</i> , 2016 , 95, e4836	1.8	5

18	Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. <i>Liver International</i> , 2021 , 41, 2059-2067	7.9	5
17	Mucocutaneous toxicity during simeprevir treatment for hepatitis C. A single institution, retrospective case series. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1152-1154	3.8	4
16	Behaviour of occult HBV infection in HCV-infected patients under treatment with direct-acting antivirals. <i>Antiviral Therapy</i> , 2019 , 24, 187-192	1.6	4
15	Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort. <i>Journal of Hepatology</i> , 2018 , 68, S83	13.4	4
14	Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017 , 66, S23-S24	13.4	3
13	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017 , 49, e60	3.3	3
12	Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. <i>Digestive and Liver Disease</i> , 2015 , 47, e6	3.3	3
11	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1190-1199	3.4	3
10	Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry. <i>Digestive and Liver Disease</i> , 2017 , 49, e6	3.3	2
9	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017 , 49, e59	3.3	2
8	Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. <i>Digestive and Liver Disease</i> , 2018 , 50, 1-2	3.3	2
7	Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity.. <i>Internal and Emergency Medicine</i> , 2022 , 1	3.7	0
6	The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance. <i>Digestive and Liver Disease</i> , 2018 , 50, 20	3.3	
5	NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C. <i>Intervirolgy</i> , 2018 , 61, 1-8	2.5	
4	SP211ACUTE KIDNEY INJURY IN CIRRHOTIC PATIENTS UNDERGOING CONTRAST-ENHANCED COMPUTED TOMOGRAPHY. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii448-iii448	4.3	
3	Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease. <i>Annals of Hepatology</i> , 2021 , 100578	3.1	
2	Cirrhotic Patients with Bacterial Infection and Negative Cultures Have a More Advanced Disease and an Increased Short-Term Mortality Rate. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	
1	Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules. <i>Internal and Emergency Medicine</i> , 2021 , 16, 949-955	3.7	

